ArticleFrontiers in pharmacology2025
Psychotropic medication use and risks of kidney injury and fall-related events: a propensity score-matched cohort study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psychotropic medications are widely prescribed, yet their long-term renal and injury-related safety in real-world populations remains incompletely defined. We examined the associations between psychotropic medication use and long-term risks of kidney injury and fall-related adverse events. Methods: We conducted a retrospective propensity score-matched cohort study using the TriNetX global federated health research network. Adults aged ≥18 years with continuous psychotropic medication use were matched 1:1 to nonusers. Primary outcomes were 5-year acute kidney injury (AKI) and chronic kidney disease (CKD). Secondary outcomes included falls, fractures, head injury, dizziness or vertigo, and rhabdomyolysis. Relative risks (RRs) and 95% confidence intervals (CIs) were estimated. Results: Among 169,309 matched pairs (mean age 47 years; 69% female), psychotropic medication use was associated with higher 5-year risks of AKI (2.85% vs. 1.55%; RR 1.83, 95% CI 1.75-1.92), incident CKD stage 3 (7.50% vs. 6.18%; RR 1.21, 95% CI 1.18-1.25), and advanced CKD (1.13% vs. 0.88%; RR 1.28, 95% CI 1.20-1.37). Increased risks were also observed for fall-related outcomes, including falls (RR 2.32), fractures (RR 1.85), head injury (RR 1.88), dizziness or vertigo (RR 1.81), and rhabdomyolysis (RR 3.71). Associations were generally consistent across medication classes, age groups, and sex. Conclusion: Psychotropic medication use was associated with modest but significantly higher long-term risks of kidney injury and fall-related events in a large real-world cohort, even after accounting for underlying psychiatric and neurologic conditions. These findings support the need for integrated renal monitoring and injury-prevention strategies in patients receiving long-term psychotropic therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.